Sudha Kilaru1, A G Christina Bergqvist1. 1. Division of Neurology, The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, U.S.A.
Abstract
PURPOSE: Myoclonic astatic epilepsy (MAE) is a generalized epilepsy of early childhood. Little is known about the use of newer antiepileptic treatments (AET) in MAE. The purpose of this study was to describe the characteristics, treatment, and outcome of a contemporary MAE cohort exposed to the new generation AET. METHODS: Charts of subjects with MAE treated between 1998 and 2005 were reviewed. RESULTS: Twenty-three subjects (19 boys), with a median (range) follow-up of 38 (2- 86) months were identified. Thirty-nine percent had a family history of epilepsy, and 39% had family history of febrile seizures. Age at seizure onset was a median of 36 (12-24) months. Initial EEG was normal in 30%. When seizures ceased, EEG background and epileptiform abnormalities persisted in 17 and 58%, respectively. On average, each subject was exposed to five AET. The most frequently used AET was valproate (83%). Seizure freedom occurred spontaneously in three subjects, with ethosuximide and levetiracetam in one each, valproate and lamotrigine in two each, topiramate in three and the ketogenic diet (KD) in five subjects. By 36 months after seizure onset, 67% achieved seizure freedom. At the last visit, 43% were developmentally normal, 52% had mild, and 5% had moderate cognitive disabilities. Time to seizure freedom did not correlate with cognitive outcome. CONCLUSIONS: The new generation of AET may offer significant benefit to children with MAE. The KD was the most effective AET in this series, and perhaps should be considered earlier in treatment.
PURPOSE:Myoclonic astatic epilepsy (MAE) is a generalized epilepsy of early childhood. Little is known about the use of newer antiepileptic treatments (AET) in MAE. The purpose of this study was to describe the characteristics, treatment, and outcome of a contemporary MAE cohort exposed to the new generation AET. METHODS: Charts of subjects with MAE treated between 1998 and 2005 were reviewed. RESULTS: Twenty-three subjects (19 boys), with a median (range) follow-up of 38 (2- 86) months were identified. Thirty-nine percent had a family history of epilepsy, and 39% had family history of febrile seizures. Age at seizure onset was a median of 36 (12-24) months. Initial EEG was normal in 30%. When seizures ceased, EEG background and epileptiform abnormalities persisted in 17 and 58%, respectively. On average, each subject was exposed to five AET. The most frequently used AET was valproate (83%). Seizure freedom occurred spontaneously in three subjects, with ethosuximide and levetiracetam in one each, valproate and lamotrigine in two each, topiramate in three and the ketogenic diet (KD) in five subjects. By 36 months after seizure onset, 67% achieved seizure freedom. At the last visit, 43% were developmentally normal, 52% had mild, and 5% had moderate cognitive disabilities. Time to seizure freedom did not correlate with cognitive outcome. CONCLUSIONS: The new generation of AET may offer significant benefit to children with MAE. The KD was the most effective AET in this series, and perhaps should be considered earlier in treatment.
Authors: Eric H Kossoff; Jennifer L Bosarge; Maria J Miranda; Adelheid Wiemer-Kruel; Hoon Chul Kang; Heung Dong Kim Journal: Epilepsia Date: 2010-11-10 Impact factor: 5.864
Authors: Sudha Kilaru Kessler; Paul R Gallagher; Renée A Shellhaas; Robert R Clancy; A G Christina Bergqvist Journal: Epilepsy Res Date: 2011-02-23 Impact factor: 3.045
Authors: Gemma L Carvill; Jacinta M McMahon; Amy Schneider; Matthew Zemel; Candace T Myers; Julia Saykally; John Nguyen; Angela Robbiano; Federico Zara; Nicola Specchio; Oriano Mecarelli; Robert L Smith; Richard J Leventer; Rikke S Møller; Marina Nikanorova; Petia Dimova; Albena Jordanova; Steven Petrou; Ingo Helbig; Pasquale Striano; Sarah Weckhuysen; Samuel F Berkovic; Ingrid E Scheffer; Heather C Mefford Journal: Am J Hum Genet Date: 2015-04-09 Impact factor: 11.025
Authors: Pasquale Parisi; Alberto Spalice; Francesco Nicita; Laura Papetti; Fabiana Ursitti; Alberto Verrotti; Paola Iannetti; Maria Pia Villa Journal: Curr Neuropharmacol Date: 2010-12 Impact factor: 7.363